KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

ClearPoint Neuro (CLPT) Depreciation and Depletion (2018 - 2019)

ClearPoint Neuro's Depreciation and Depletion history spans 2 years, with the latest figure at $35710.0 for Q3 2019.

On a quarterly basis, Depreciation and Depletion rose 38.48% to $35710.0 in Q3 2019 year-over-year; TTM through Sep 2019 was $131098.0, a N/A change, with the full-year FY2025 number at $400000.0, up 100.0% from a year prior.
Depreciation and Depletion hit $35710.0 in Q3 2019 for ClearPoint Neuro, up from $34960.0 in the prior quarter.
Over the last five years, Depreciation and Depletion for CLPT hit a ceiling of $35710.0 in Q3 2019 and a floor of $23795.0 in Q2 2018.